TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00527475

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: 0.5 mg. given as an intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab
Description: 0.5 mg. given as an intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verteporfin
Description: Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
Study: NCT02316340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: 400mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 600mg by mouth daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg by mouth daily
Study: NCT04462562

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Quantitative US (Samsung Medison, RS85A)
Description: In each patients, measurements of tissue attenuation imagine (TAI), tissue scatter-distribution imaging (TSI) parameters, hepatorenal index (EzHRI) will be performed
Study: NCT01859832

Intervention type: OTHER
Intervention: Cylex ImmuKnow Assay
Description: This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
Study: NCT04790877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 1
Description: Subjects were provided with: a) Glucose beverage; b) Regular alcohol-free beer; c) Alcohol-free beer with modified composition (isomaltulose + maltodextrin); d) Alcohol-free beer with modified composition (++ maltodextrin).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-study 2
Description: Subjects were provided with: a) White bread + Water; b) White bread + Regular alcohol-free beer; c) White bread+Alcohol-free beer enriched with isomaltulose+maltodextrin); d) White bread + Alcohol-free beer enriched with ++ maltodextrin; e) Extra-White bread + Water.
Study: NCT05352204

Intervention type: PROCEDURE
Intervention: transcatheter arterial chemoembolization
Description: transcatheter arterial chemoembolization after liver resection
Study: NCT02515110

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo hypofractionated RNI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04329702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training mobile app with call from CST therapist
Description: The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. A therapist will call participant to introduce the intervention and perform a brief relaxation exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping skills training mobile app only
Description: The intervention is a mobile app that delivers a 4-week long program of coping skills training. The app contains video, visual, and text content and has a companion PDF workbook. It provides timeline-driven prompts to complete weekly tasks (e.g., viewing videos, completing surveys) and coaching participants to use their current stressors as context for real-life application of adaptive coping skills. App chat room access will be provided.
Study: NCT01630473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy
Description: After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orthodontics
Description: Conventional orthodontic treatment
Study: NCT00533832

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vagus nerve stimulation (VNS)
Description: intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: vagus nerve stimulation (VNS)
Description: intermittent vagus nerve stimulation~Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase.
Study: NCT04122014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive balance training
Description: Progressive balance training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal daily activities
Description: Usual daily activities
Study: NCT03915015

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: MRI
Study: NCT04543071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Motixafortide
Description: 1.25 mg/kg subcutaneous (SC) monotherapy daily for 5 days during priming, followed by twice weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg intravenous (IV) once every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV on days days 1, 8, 14 (every 28 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125 mg/m2 IV on days 1, 8, 14 (every 28 days)
Study: NCT03005795

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Headphones
Description: Music can be heard through headphones

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Headphones
Description: No Headphones will be used.
Study: NCT00971451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: 20 minutes of knee joint cryotherapy - ice bag application

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS
Description: continuous use of TENS during the exercise session
Study: NCT03100045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Suppositories
Description: Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
Study: NCT00952497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Capecitabine, Telatinib
Description: Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
Study: NCT03129321

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Econazole Nitrate Cream, 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Econazole Nitrate Cream, 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01971073

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.~The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions ).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
Study: NCT02353156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic bidet
Description: electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sitz bath
Description: sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
Study: NCT00067028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine 40mg/m^2
Description: 40 mg/m\^2 by vein over 1 hour daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin 10mg/m^2
Description: 10 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.~Clofarabine + Idarubicin plus Ara-C:~6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C 0.75 g/m^2
Description: 0.75 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine 22.5mg/m^2
Description: 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine 22.5mg/m^2
Description: 22.5 mg/m\^2 by vein over 1 hour daily for 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C 1 g/m^2
Description: 1 g/m\^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin 6 mg/m^2
Description: 6 mg/m\^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Study: NCT02534402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Administration of prednisone to determine the effect on whole blood gene expression.
Study: NCT02789904

Intervention type: OTHER
Intervention: blood taking
Description: Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
Study: NCT00916188

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Black Tea Extract
Description: Amount/dose depends on Arm assignment.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black Tea Extract
Description: Amount/dose depends on Arm assignment.
Study: NCT04531696

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood draw
Description: Blood draw at inclusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Post-mortem tissue collection
Description: Sample collection (both liquids, tumour tissue and non-tumour tissue) during post-mortem research autopsy
Study: NCT00112671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally 400mg orally twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT06211894

Intervention type: PROCEDURE
Intervention: transobturator tape
Description: transobturator tape :The surgeon makes a small incision in the vagina and small incisions in the right and left groin. The surgical process is similar to the retropubic approach, but the mesh passes through the groin muscles rather than the abdominal wall. transperineal ultrasound: patients who underwent TOT and were evaluated with transperineal ultrasonography, women with incontinence 6 months after the surgery showed discrepancies in the movement of the urethra with the sling compared to continent women, along with asymmetry between the mesh arms, bladder neck descent, and varied sling positions.
Study: NCT02253862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Description: administered days 8-18

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: administered days 8-18
Study: NCT02104986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velbe-Bleomycin-Cisplatin
Description: Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velbe-Bleomycin-Cisplatin
Description: Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepeside-ifosfamide-Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vepeside-ifosfamide-Cisplatin
Study: NCT02841397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Pulse CO-Oximeter
Description: Noninvasive pulse oximeter with various features for measurement of hemoglobin, pleth variability index, and oxygen reserve index
Study: NCT05404464

Intervention type: OTHER
Intervention: Different baseline characteristics and clinical management
Description: Personal history, basic diseases, stimulation plan, type of ART, transplantation strategy, etc.
Study: NCT02902250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: vertebral body decompression in compression fracture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Conservative Treatment in vertebral compression fracture
Study: NCT02093806

Intervention type: OTHER
Intervention: measurment
Study: NCT02757599

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound training
Description: Training on the transvaginal ultrasound simulator.

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasound training
Description: Training on the transvaginal ultrasound simulator.
Study: NCT03769246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Upright Go Device
Description: Participants will be asked to use the Upright device everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic Handout
Description: Participants will be asked to use the ergonomic handout everyday for four (4) weeks. After four (4) weeks, the participants will be asked to complete a couple of questionnaires regarding their pain scale and back posture.
Study: NCT02343159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: 120 mg and 240 mg delayed release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: 120 mg and 240 mg delayed release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate
Description: 120 mg and 240 mg delayed release capsules

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS)
Description: The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence counseling
Description: A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
Study: NCT01647451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0114-0006
Description: Two i.v. (intravenous) doses administered 6 weeks apart.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Two i.v. (intravenous) doses administered 6 weeks apart.
Study: NCT01147328

Intervention type: OTHER
Intervention: Virtual Health Record (VHR)
Description: Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.

Intervention type: OTHER
Intervention: Virtual Health Record (VHR)
Description: Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
Study: NCT03703102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: Anti-OX40 Monoclonal Antibody KHK4083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: Anti-OX40 Monoclonal Antibody KHK4083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: Anti-OX40 Monoclonal Antibody KHK4083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4083
Description: Anti-OX40 Monoclonal Antibody KHK4083

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT02458963

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF
Description: Women will undergo one IVF cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonadotropin
Description: Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
Study: NCT03433872

Intervention type: OTHER
Group type: OTHER
Intervention: We Grow Together: The Q-CCIIT Professional Development System
Description: We Grow Together is designed to strengthen high quality caregiver interactions with infants and toddlers. The starting point for the We Grow Together study is assessment of a caregiver's interactions with infants and toddlers in the caregiver's ECE setting, using the Q-CCIIT observational measure. Data from the Q CCIIT observations highlight areas for growth in the caregiver's practices and will inform a PD goal-setting process, with the help of a PD Provider. An array of We Grow Together materials targeting practices assessed by the Q-CCIIT measure and informed by professional development and behavior change research are organized into modules, and delivered on an interactive website. Over the course of a program year, each caregiver in the study will work with a PD provider who is trained in guiding caregivers through the use of We Grow Together materials.
Study: NCT03633175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal progesterone
Description: 400 mg vaginal progesterone \[Prontogest® vaginal pessaries 400, Marcyrl, Cairo, Egypt\] will be given, once at bed time starting from 26-28 weeks of gestation till 36 weeks of gestation or delivery (which is closer).
Study: NCT03001089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Fludrocortisone (enteral)
Description: Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
Study: NCT03997435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control arm
Description: neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental arm
Description: Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.
Study: NCT04542759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besifloxacin Ophthalmic
Description: Prophylaxis for endophthalmitis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxypropyl Methylcellulose Ophthalmic Ophthalmic Solution
Description: Placebo